Condition: Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Sponsor: Terrence J Bradley, MD
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
This description comes directly from the study's public registry record.
Alessia Zoso, PhD · 305-243-2373 · azoso@med.miami.edu
Terrence J Bradley, MD · 305-243-1000 · tbradley@med.miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05597306